HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating on Atara Biotherapeutics, indicating no change in their stance on the company's stock.
August 21, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Atara Biotherapeutics, suggesting that the analyst sees no immediate catalysts for significant stock movement.
The reiteration of a Neutral rating by HC Wainwright & Co. suggests that the analyst does not foresee any significant positive or negative catalysts for Atara Biotherapeutics in the short term. This typically indicates that the stock is expected to perform in line with the market or sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100